- Telix Pharmaceuticals (TLX) has entered a multimillion-dollar strategic partnership with China Grand Pharmaceutical and Healthcare Holdings (CGP)
- The products are used in medical imaging of the brain, prostate, and renal cancer
- The partnership will have a 10-year term, following the granting of marketing authorization for each product
- Telix Pharmaceuticals CEO Dr. Chris Behrenbruch said the company believes CGP is the ideal partner for the region
- CGP will also make a strategic investment in Telix which will secure it a 7.62 percent interest in the company
- TLX shares closed 29 percent higher at $2.16
